• Fast-Tracking Clinical Readiness: The agreement enables process and analytical development activities required to advance Nimvec™ AM510 for Type 1 Diabetes toward cGMP manufacturing and first-in-human clinical trials

• Strengthening the Amarna–NorthX Biologics Alliance: This milestone marks a significant step forward in the companies’ shared vision to bring innovative gene therapies to patients with unmet medical needs

Amarna Therapeutics, (“Amarna” or “the Company”), a privately held biotechnology company pioneering transformative gene therapies, today announced the formalization of an agreement with NorthX Biologics, a leading biologics manufacturing partner, to accelerate the development of Nimvec™, Amarna’s next-generation gene therapy platform targeting immune-mediated diseases. This agreement builds on the strategic partnership announced last year, which initiated the transfer of Amarna’s research-scale production process for Nimvec™ AM510 to NorthX Biologics.

The initial focus remains on Type 1 Diabetes, where Nimvec™ AM510 is designed to restore immune tolerance to insulin-producing beta cells by targeting proinsulin. Proinsulin is the primary antigen that triggers the autoimmune attack on beta cells, so by restoring tolerance to it, the therapy aims to halt autoimmune destruction at its source. By combining Amarna’s proprietary Nimvec™ platform with NorthX Biologics’ world-class manufacturing expertise, the collaboration is laying the foundation for robust, scalable, and regulatory-compliant manufacturing processes to support future clinical trials.

Strengthening the Path Toward Clinical Readiness

Under the terms of the agreement, Amarna enables the transfer and optimization of Amarna’s research-scale production process for Nimvec™ AM510 to NorthX Biologics’ advanced development facilities. It includes a comprehensive analytical development package aimed at ensuring the identity, potency, and quality of the vector throughout its development lifecycle.

“This agreement represents a major advancement in our partnership with NorthX Biologics and a critical step toward bringing Nimvec™ AM510 to patients,” said Dr. Henk Streefkerk, CEO of Amarna Therapeutics. “With this investment, we are accelerating our path to clinical trials and moving closer to providing a potential cure for Type 1 Diabetes. Collaborating with NorthX Biologics enables us to build a solid CMC foundation, ensuring we are well-prepared for the next phases of development. We're eager to see our first clinical-grade batch produced.

A Shared Commitment to Scalable Innovation

This agreement underscores their shared mission to accelerate the development of scalable, high-quality gene therapies.

“We are proud to deepen our collaboration with Amarna and support the progression of Nimvec™ AM510,” said Dr. Janet Hoogstraate, CEO of NorthX Biologics. “Our combined expertise will help ensure the highest standards in process development and manufacturing as we advance this promising therapy.”